Mestag Therapeutics

About Mestag Therapeutics

Mestag Therapeutics is focused on developing new therapies for cancer and inflammatory diseases by harnessing fibroblast immunology. Their mission is to re-establish the immune system's proper function for patients who do not benefit from current treatments, aiming to significantly improve lives affected by these conditions.

Products & Services

M300:A bispecific antibody designed to generate a robust and specialized immune response against cancer cells by forming tertiary lymphoid structures (TLSs) in solid tumors. It is rapidly progressing towards its first clinical trial.

M402 Program:Pioneering agonist antibodies targeting a stromal inhibitory receptor to dampen an over-active immune system, addressing unmet needs in inflammatory diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and lupus.

Specialties

Fibroblast Immunology Immunotherapy Cancer Treatment Inflammatory Disease Treatment Antibody Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1900000 MR: - FA: £1.5 million FAN: 1900000	D: 2024-08-28 FD: 2024-08-28	1 investors

Grant Latest

2024-08-28

$1.9M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sarah Smith

Senior Project Manager

R

Robert de Jonge

SVP, Head of Corporate Development

S

Sameer Sirohi

Principal Scientist I

E

Eilidh Goodwin

Vice President, Finance and Operations

L

Lucy Penfold

Principal Scientist I

S

Susan Hill

Chief Executive Officer

View 31 more team members with Pro

Unlock Full Team Directory

Recent News